INDUSTRIALISATION
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK
Subscribe
INDUSTRIALISATION
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK
SEARCH
SEARCH
advanced search
PULMONARY
INDUSTRIALISATION
Lorenzo Vaccarella
Paragon Medical
FUTURE-PROOFING YOUR DRUG DELIVERY DEVICE: CONSIDERATIONS FOR EFFECTIVE DESIGN
Lorenzo Vaccarella highlights six critical areas to consider early in the drug delivery device development journey. He discusses how strategically investing time during the early stages of the design cycle and throughout development can ultimately save both time and cost down the road when the product is being manufactured and deployed into the market.
CONNECTIVITY
Dr Carola Fuchs
PARI
OPTIMISING INHALATION ADHERENCE AND TECHNIQUE: THE POWER OF DIGITAL TECHNOLOGY
Carola Fuchs and Rupa Ram discuss the development of PARI’s new eFlow Integrated Nebuliser and the PARI Breath Guide app, and how integrating these into the PARI Connect Platform will stimulate increased adherence to inhaled therapy and, therefore, improved therapeutic outcomes.
EXPERT VIEW
Dr Timothy Noakes
NAVIGATING THE TRANSITION TO SUSTAINABLE MEDICAL PROPELLANTS
Timothy Noakes, Sheryl Johnson and Richard Greenhough, discuss the status of the current move from high-global-warming-potential propellants for pressurised metered dose inhalers to more sustainable alternatives.
SUSTAINABILITY
Dr Benjamin Myatt
Kindeva
OPTIMISING LOW-GWP pMDI SPRAYS FOR ENHANCED PERFORMANCE AND SUSTAINABILITY
Benjamin Myatt and Daniel Duke explore the low-global-warming-potential propellants available and their implications for the performance of pressurised metered dose inhalers.
EXPERT VIEW
Pauline Janssen
CHANGE IS IN THE AIR: THE FUTURE CLIMATE OF INHALED MEDICATION
Pauline Janssen, discusses the various available devices for pulmonary delivery of medications, with a deeper dive into the challenges presented by replacing pMDI propellants with high global warming potential with new alternatives, or whether the optimal solution could be phasing out pMDIs in favour of DPIs.
EXPERT VIEW
Catriona Eldridge
PHARMACEUTICAL INDUSTRY SUSTAINABILITY TARGETS, ONE YEAR ON
Catriona Eldridge, analyses whether the pharmaceutical industry is meeting its targets and doing enough in the fight against climate change.
EXPERT VIEW
Dr Zaid Aqrawe
Merxin Ltd
SOFT MIST INHALERS VERSUS NEBULISERS: DELIVERY EQUIVALENCE & FUTURE THERAPIES
Zaid Aqrawe, Philippe Rogueda, Darragh Murnane and Bryan Eng, discuss the opportunity presented by soft mist inhalers as an alternative delivery device to nebulisers for inhaled therapies, contrasting the two device categories across multiple factors.
INDUSTRIALISATION
Marcus Jarman-Smith
Victrex
ADVANCING PHARMACEUTICAL CONTACT APPLICATIONS WITH PEEK: MEETING INCREASING DEMANDS
Marcus Jarman-Smith and Yann Tréguier, discuss the myriad benefits that Victrex’s pharmaceutical-grade PEEK can offer to the drug delivery sector as a material of construction due to its versatile material properties.
PULMONARY
Dr Susana Saldanha
Hovione
HIGH-DOSE DELIVERY PLATFORM FOR CRYSTALLINE DPIs
Susana Saldanha, Lídia Santos and Rui Churro, discuss the benefits of crystalline formulations for inhalation devices.
INDUSTRIALISATION
Dr Alan Watts
Catalent Pharma Solutions
ARCUS
®
: A COMMERCIALISED TECHNOLOGY ENABLING HIGH-DOSE, HIGHLY RESPIRABLE POWDERS
Alan Watts and Michael Tauber, discuss the requirements and benefits of using spray-dried powders for inhalation, and how ARCUS, used for the successfully commercialised Inbrija® dry powder inhaler, is a prime example of this technology in action.
RESPIRATORY
Gemma Budd
Aptar Pharma
ADVANCING OINDP CLINICAL TRIALS WITH SPEED AND EFFICIENCY: STRATEGIES FOR SUCCESS
Gemma Budd and Julie Suman, consider the key issues that preclinical and clinical trials for orally inhaled and nasal drug products must address within the context of the information that regulators are looking for, providing insight, strategies and advice for both novel and generic products in this sector.
PULMONARY
Matthew Fenn
Copley Scientific
BETTER IN VIVO PREDICTION FROM OINDP TESTING: A GOAL WORTH PURSUING?
Matthew Fenn and Clair Brooks, consider the motivation for adopting more clinically representative test set-ups in orally inhaled and nasal drug product development and, more specifically, for the demonstration of bioequivalence, as well as the practicalities of doing so and the tools available to support such efforts.
INTERVIEW
Dr Sandy Munro
Phillips Medisize
Interview with Sandy Munro, Vectura
In this exclusive interview with ONdrugDelivery’s Guy Furness, Sandy Munro, PhD, of Vectura discusses his extensive career, focused on respiratory drug delivery. He shares his insights into current trends within the industry, including the growth of biologics, systemic delivery via inhalation, the potential of mesh nebulisers and connectivity in clinical trials.
PULMONARY
Gesa Braunlich
PARI
DEEP BREATHS, DEEP DIVES: THE NEW eFLOW INTEGRATED NEBULISER
Gesa Bräunlich and Michael Hahn discuss PARI’s new eFlow integrated nebuliser.
RESPIRATORY
Mike Needham
Kindeva
THE EVOLUTION OF PULMONARY & NASAL DRUG DELIVERY
Mike Needham takes a look at the history of, and progress in, inhalation technology and discusses what might lie ahead.
EXPERT VIEW
Dr Ethan Miller
BUBBLE-WRAPPED REMEDIES: HOW LIPID-ENCASED THERAPEUTICS COULD TRANSFORM INHALATION
Ethan Miller and Heather Jameson shed light on some of the intricacies that lipid-encapsulated therapeutics bring to the realm of inhalation therapies, and some considerations on how the type of inhalation device selected may help to mitigate issues around formulation stability and efficient delivery to target cells.
EXPERT VIEW
Dr Carolina Dantas
EXPLORING THE POTENTIAL OF NEBULISED BIOLOGICS
Carolina Dantas and Ulf Krueger consider the challenges when it comes to the successful delivery of inhaled biological drugs.
PREFILLED SYRINGES
Alastair Willoughby
Team Consulting
DISCUSSION PRIMER: PHARMAPACK
Pharmapack’s organisers spoke with three industry experts, Alastair Willoughby, Jamie Greenwood and Chris Hurlstone, all from Team Consulting, to get their perspectives on the major trends expected to be top discussion topics at the event, and to play a significant role in the industry throughout 2024 and beyond.
CONNECTIVITY
Edgar Hernan Cuevas Brun
HCmed Innovations
CUSTOMISABLE NEBULISER PLATFORM TO MONITOR ADHERENCE
Edgar Hernan Cuevas Brun and Yuan-Ming Hsu discuss the value that customisable nebuliser platforms bring to patient adherence.
CONNECTIVITY
Joachim Koerner
Aptar Digital Health
IMPROVING MEDICATION ADHERENCE AND CLINICAL OUTCOMES THROUGH CONNECTED DRUG DELIVERY DEVICES
Joachim Koerner and Marcus Bates discuss the challenge that medication non-adherence presents to the healthcare sector, and the potential value of connected digital health solutions as a way of overcoming this challenge.
PULMONARY
Carolyn Berg
Catalent Pharma Solutions
SMART SCALING FOR SUCCESSFUL CAPSULE-BASED DRY POWDER INHALER FILLING USING DRUM TECHNOLOGIES
Carolyn Berg, William Chin and Patrick Goncalves discuss the considerations for filling capsules for dry powder inhalers across the various stages of clinical trials and commercialisation, and how to tackle the challenges of scaling up filling processes.
PULMONARY
Gladys Corrons-Bouis
Eveon
SPRAY DELIVERY: TARGETING PATIENT NEEDS AND EXPECTATIONS WITH PRECISION
Gladys Corrons-Bouis and Cyril Le Loc’h discuss the use of spray delivery for precise targeting of patient medication.
EXPERT VIEW
Ross Errington
FUTURE-PROOFING pMDI DESIGN TO FIT A CHANGING MARKET
Ross Errington explores how pharmaceutical companies can evolve their pMDI drug products to make them fit for the future considering the several recent regulatory changes that are transforming the landscape of inhalation drugs.
EXPERT VIEW
Finn Heraghty
THE END OF THE ROAD FOR pMDIs?
Finn Heraghty and Heather Jameson explore the extent to which the healthcare needs of a population could be covered by the combined use of soft mist inhalers and dry powder inhalers, and discuss the factors that will impact the continued importance of pressurised metered dose inhalers going forward.
Prev
1
2
3
4
5
…
14
Next
Top
